Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032... see more

Recent & Breaking News (NDAQ:ANAB)

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

GlobeNewswire September 12, 2023

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 7, 2023

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GlobeNewswire July 31, 2023

AnaptysBio Announces Participation in Upcoming Investor Conferences

GlobeNewswire May 30, 2023

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

GlobeNewswire May 11, 2023

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

GlobeNewswire May 2, 2023

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

GlobeNewswire April 6, 2023

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial

GlobeNewswire March 27, 2023

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 1, 2023

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

GlobeNewswire February 27, 2023

AnaptysBio Announces Stock Repurchase Plan

GlobeNewswire January 13, 2023

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

GlobeNewswire January 5, 2023

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

GlobeNewswire December 2, 2022

AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

GlobeNewswire November 21, 2022

AnaptysBio to Participate in Upcoming November Investor Conferences

GlobeNewswire November 9, 2022

AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update

GlobeNewswire November 8, 2022

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials

GlobeNewswire October 5, 2022

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

GlobeNewswire September 26, 2022

AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million

GlobeNewswire September 12, 2022

AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

GlobeNewswire August 31, 2022